{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:31:19Z","timestamp":1790753479028,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004571","name":"Minist\u00e8re des Affaires Sociales et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.autrev.2020.102726","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T02:49:38Z","timestamp":1608000578000},"page":"102726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study."],"prefix":"10.1016","volume":"20","author":[{"given":"Gilles","family":"Kaplanski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Bontemps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Esnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Carvelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Delarbre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Cauchois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Forel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Papazian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102726_bb0005","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591 patients infected With SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2020.102726_bb0010","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa2004500","article-title":"Covid-19 in critically ill patients in the Seattle region - case series","volume":"382","author":"Bhatraju","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102726_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.04.027","article-title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19","author":"Yang","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2020.102726_bb0020","article-title":"Weathering the COVID-19 storm: lessons from hematologic cytokine syndromes","author":"England","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.autrev.2020.102726_bb0025","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102726_bb0030","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1182\/bloodadvances.2019000898","article-title":"Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1\/2 inhibitor ruxolitinib","volume":"3","author":"Goldsmith","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2020.102726_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2020.102726_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2020.102726_bb0045","doi-asserted-by":"crossref","first-page":"18951","DOI":"10.1073\/pnas.2009017117","article-title":"Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19","volume":"117","author":"Cauchois","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.autrev.2020.102726_bb0050","first-page":"529","article-title":"Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19","volume":"38","author":"Sciascia","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2020.102726_bb0055","article-title":"Dexamethasone in hospitalized patients with Covid-19 - preliminary report","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102726_bb0060","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd1554","article-title":"Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.autrev.2020.102726_bb0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.autrev.2020.102726_bb0070","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2020.102726_bb0075","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00134-019-05847-z","article-title":"ECLS-associated infections in adults: what we know and what we don\u2019t yet know","volume":"46","author":"Abrams","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.autrev.2020.102726_bb0080","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019003664","article-title":"Functional and genetic testing in adults with hlh do not reveal a cytotoxicity defect but rather an inflammatory profile","author":"Carvelli","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102726_bb0085","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220303074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220303074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:20:31Z","timestamp":1761600031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220303074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1568997220303074"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102726","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study.","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102726","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102726"}}